Olefir Y.V. Yu V
Yavorskii A.N.
Butnaru D.V.
Shatalova O.V.
Gorbatenko V.S.
Gerasimenko A.S.
I.M. Sechenov First MSMU, Moscow, Russia.
Scientific Centre for Expert Evaluation of Medicinal Products, Moscow, Russia.
Volgograd State Medical University of the Ministry of Health of Russia, Volgograd, Russia.
Idiopathic hypercalciuria. Diagnosis and treatment
Текст визуальный электронный
Urologiia (Moscow, Russia : 1999)
№ 6 С. 112-119
2017
bisphosphonates
idiopathic hypercalciuria
nephrolithiasis
polymorphism of the vitamin D receptor gene
Статья
Обзор
Alendronate therapeutic use D02.705.429.500.100
Алендронат терапевтическое применение D02.705.429.500.100
Female
Женский
Humans B01.050.150.900.649.313.988.400.112.400.400
Человек B01.050.150.900.649.313.988.400.112.400.400
Hypercalciuria diagnosis C23.888.942.337
Hypercalciuria drug therapy C23.888.942.337
Hypercalciuria genetics C23.888.942.337
Hypercalciuria metabolism C23.888.942.337
Гиперкальциурия диагностика C23.888.942.337
Гиперкальциурия лекарственная терапия C23.888.942.337
Гиперкальциурия генетика C23.888.942.337
Гиперкальциурия метаболизм C23.888.942.337
Male
Мужской
Mutation G05.365.590
Мутация G05.365.590
Nephrolithiasis C12.050.351.968.419.600 C12.050.351.968.967.249 C12.200.777.419.600 C12.200.777.967.249 C12.950.419.600 C12.950.967.249
Nephrolithiasis diagnosis C12.050.351.968.419.600 C12.050.351.968.967.249 C12.200.777.419.600 C12.200.777.967.249 C12.950.419.600 C12.950.967.249
Nephrolithiasis drug therapy C12.050.351.968.419.600 C12.050.351.968.967.249 C12.200.777.419.600 C12.200.777.967.249 C12.950.419.600 C12.950.967.249
Nephrolithiasis genetics C12.050.351.968.419.600 C12.050.351.968.967.249 C12.200.777.419.600 C12.200.777.967.249 C12.950.419.600 C12.950.967.249
Nephrolithiasis metabolism C12.050.351.968.419.600 C12.050.351.968.967.249 C12.200.777.419.600 C12.200.777.967.249 C12.950.419.600 C12.950.967.249
Нефролитиаз C12.050.351.968.419.600 C12.050.351.968.967.249 C12.200.777.419.600 C12.200.777.967.249 C12.950.419.600 C12.950.967.249
Нефролитиаз диагностика C12.050.351.968.419.600 C12.050.351.968.967.249 C12.200.777.419.600 C12.200.777.967.249 C12.950.419.600 C12.950.967.249
Нефролитиаз лекарственная терапия C12.050.351.968.419.600 C12.050.351.968.967.249 C12.200.777.419.600 C12.200.777.967.249 C12.950.419.600 C12.950.967.249
Нефролитиаз генетика C12.050.351.968.419.600 C12.050.351.968.967.249 C12.200.777.419.600 C12.200.777.967.249 C12.950.419.600 C12.950.967.249
Нефролитиаз метаболизм C12.050.351.968.419.600 C12.050.351.968.967.249 C12.200.777.419.600 C12.200.777.967.249 C12.950.419.600 C12.950.967.249
Receptors, Calcitriol D12.776.826.535
Receptors, Calcitriol genetics D12.776.826.535
Receptors, Calcitriol metabolism D12.776.826.535
Рецепторы кальцитриола D12.776.826.535
Рецепторы кальцитриола генетика D12.776.826.535
Рецепторы кальцитриола метаболизм D12.776.826.535
Journal Article V02.600
Журнальная статья V02.600
Review V02.600.500 V02.912
Обзор V02.600.500 V02.912
Systematic Review V03.850
Систематический обзор V03.850
Most patients with idiopathic hypercalciuria and calcium nephrolithiasis have a family history of the disease. Idiopathic hypercalciuria is a metabolic abnormality with various causes and developmental pathways. The systematic review describes specific mutations associated with idiopathic hypercalciuria and nephrolithiasis. Detection of these mutations may provide a better understanding of the pathogenesis of this heterogeneous disease and personalize patient management depending on the detected polymorphisms. A promising treatment option for a mutation in the vitamin D receptor gene is thiazide diuretics in combination with bisphosphonates. Among bisphosphonates, the drug of choice which has been most strongly supported by research evidence is alendronate.